HIV Infection Rather than Concurrent Opportunistic Infections drives Most Systemic Procoagulant,Vascular and Damage Responses – a Prospective Cohort Study in Central Africa

Abstract

Background

HIV infection is accompanied by various systemic host responses, including activation of coagulation and the vascular endothelium. We sought to determine the impact of opportunistic coinfections in a central African setting.

Methods

This prospective study included 98 HIV-infected individuals in Gabon initiating combination antiretroviral therapy (cART) and followed them up for 6 months. Patients were stratified according to the presence of active tuberculosis (TB; n=19), mucocutaneous opportunistic infection (n=9) or no opportunistic infection (n=70). HIV-uninfected subjects were included as controls (n=32). Plasma concentrations of 14 markers of coagulation, endothelial activation, extracellular matrix formation and tissue damage were measured with a multiplex assay at baseline and months 3 and 6 after cART initiation.

Results

HIV-infected patients showed elevated plasma levels of all biomarkers measured with exception of protein C, which was reduced. Concurrent TB was only associated with elevated concentrations of D-dimer, metal-lopeptidase inhibitor 1 and Tenascin-C. Mucocutaneous coinfection did not alter HIV-associated responses. Most markers measured declined but remained elevated despite response to cART.

Conclusions

HIV infection is associated with systemic pro-coagulant, vascular and damage responses. In an ambulatory setting, concurrent opportunistic infections have little if any influence on these responses and normalization is incomplete after response to cART. This suggests that these responses are mainly driven by HIV-associated immune activation and less so by opportunistic infections.

References

UNAIDS. Report on the Global AIDS Epidemic 2013. (Accessed 1 June 2016.) Available from http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf.

Klein

S.K.

, Slim

E.J.

, de Kruif

M.D.

Is chronic HIV infection associated with venous thrombotic disease? A systematic review.

Neth J Med 2005; 63: 129–136.

Fultz

S.L.

, McGinnis

K.A.

, Skanderson

, Ragni

M.V.

, Justice

A.C.

Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans.

Am J Med 2004; 116: 420–423.

Duprez

D.A.

, Neuhaus

, Kuller

L.H.

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals.

PLoS One 2012; 7: e44454.

Kuller

L.H.

, Tracy

, Belloso

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.

PLoS Med 2008; 5: e203.

Feffer

S.E.

, Fox

R.L.

, Orsen

M.M.

, Harjai

K.J.

, Glatt

A.E.

Thrombotic tendencies and correlation with clinical status in patients infected with HIV.

South Med J 1995; 88: 1126–1130.

Funderburg

N.T.

Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients.

Curr Opin HIV AIDS 2014; 9: 80–86.

Graham

S.M.

, Mwilu

, Liles

W.C.

Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: a systematic review.

Virulence 2013; 4: 564–571.

Jong

, Louw

, van Gorp

E.C.

, Meijers

J.C.

, ten Cate

, Jacobson

B F.

The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals.

Thromb Haemost 2010; 104: 1228–1234.

10.

Schved

J.F.

, Gris

J.C.

, Arnaud

von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator.

J Lab Clin Med 1992; 120: 411–419.

11.

Justice

A.C.

, Freiberg

M.S.

, Tracy

Does an index composed of clinical data refect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV?

Clin Infect Dis 2012; 54: 984–994.

12.

Aukrust

, Bjornsen

, Lunden

Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy.

Thromb Haemost 2000; 84: 183–187.

13.

Calza

, Pocaterra

, Pavoni

Plasma levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls.

J Acquir Immune Defic Syndr 2009; 50: 430–432.

14.

Gattegno

, Bentata-Peyssare

, Gronowski

, Chaouche

, Ferriere

Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) and of vascular cell adhesion molecule 1 (VCAM-1) in HIV-1 infection.

Cell Adhes Commun 1995; 3: 179–185.

15.

Cerrato

, D'Ascenzo

, Biondi-Zoccai

Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era.

Eur Heart J 2013; 34: 1432–1436.

16.

Rosenberg

A.Z.

, Naicker

, Winkler

C.A.

, Kopp

J.B.

HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment.

Nat Rev Nephrol 2015; 11: 150–160.

17.

Marchetti

, Tincati

, Silvestri

Microbial translocation in the pathogenesis of HIV infection and AIDS.

Clin Microbiol Rev 2013; 26: 2–18.

18.

Kager

L.M.

, Blok

D.C.

, Lede

I.O.

Pulmonary tuberculosis induces a systemic hypercoagulable state.

J Infect 2015; 70: 324–334.

19.

Elkington

P.T.

, Ugarte-Gil

C.A.

, Friedland

J.S.

Matrix metalloproteinases in tuberculosis.

Eur Respir J 2011; 38: 456–464.

20.

Hoheisel

, Sack

, Hui

D.S.

Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.

Tuberculosis (Edinb) 2001; 81: 203–209.

21.

Janssen

, Hermans

, Knap

Impact of anti-retroviral treatment and cotrimoxazole prophylaxis on helminth infections in HIV-infected patients in Lambarene, Gabon.

PLoS Negl Trop Dis 2015; 9: e0003769.

22.

Janssen

, Wieten

R.W.

, Stolp

Factors associated with retention to care in an HIV clinic in Gabon, Central Africa.

PLoS One 2015; 10: e0140746.

23.

World Health Organization. Tuberculosis country profile Gabon. (Accessed 1 June 2016.) Available from https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=GA&LAN=EN&outtype=html2014.

24.

World Health Organization. Antiretroviral therapy for HIV-infection in adults and adolescents – 2010 revision. (Accessed 1 June 2016.) Available from http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.

25.

Heller

, Wallrauch

, Lessells

R.J.

, Goblirsch

, Brunetti

Short course for focused assessment with sonography for human immunodeficiency virus/tuberculosis: preliminary results in a rural setting in South Africa with high prevalence of human immunodeficiency virus and tuberculosis.

Am J Trop Med Hyg 2010; 82: 512–515.

26.

Janssen

, Grobusch

M.P.

, Heller

‘Remote FASH’ tele-sonography - a novel tool to assist diagnosing HIV-associated extrapulmonary tuberculosis in remote areas.

Acta Trop 2013; 127: 53–55.

27.

International Union Against Tuberculosis and Lung Disease. Sputum examination for tuberculosis by direct microscopy in low income countries – technical guide, fifth edition 2000. (Accessed 20 May 2016.) Available from http://www.uphs.upenn.edu/bugdrug/antibiotic_manual/IUATLD_afb%20microscopy_guide.pdf.

28.

De Groote

M.A.

, Nahid

, Jarlsberg

Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.

PLoS One 2013; 8: e61002.

29.

Walzl

, Ronacher

, Hanekom

, Scriba

T.J.

, Zumla

Immunological biomarkers of tuberculosis.

Nat Rev Immunol 2011; 11: 343–354.

30.

Iglesias

, Alegre

, Aleman

Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions.

Eur Respir J 2005; 25: 104–109.

31.

Hasibuan

F.M.

, Shiratori

, Senoputra

M.A.

Evaluation of matricellular proteins in systemic and local immune response to Mycobacterium tuberculosis infection.

Microbiol Immunol 2015; 59: 623–632.

32.

Neuhaus

, Jacobs

D.R.

Jr. , Baker

J.V.

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.

J Infect Dis 2010; 201: 1788–1795.

33.

Opal

S.M.

, van der Poll

Endothelial barrier dysfunction in septic shock.

J Intern Med 2015; 277: 277–293.

34.

Graham

S.M.

, Rajwans

, Jaoko

Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression.

AIDS 2013; 27: 1803–1813.

35.

Chiquet-Ehrismann

, Chiquet

Tenascins: regulation and putative functions during pathological stress.

J Pathol 2003; 200: 488–499.

36.

Demacq

, Vasconcellos

V.B.

, Marcaccini

A.M.

, Gerlach

R.F.

, Machado

A.A.

, Tanus-Santos

J.E.

A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients.

Pharmacogenomics J 2009; 9: 265–273.

37.

Diaz

, Garcia

, Mozos

Lymphoid tissue collagen deposition in HIV-infected patients correlates with the imbalance between matrix metalloproteinases and their inhibitors.

J Infect Dis 2011; 203: 810–813.

38.

Parikh

C.R.

, Coca

S.G.

, Thiessen-Philbrook

Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery.

J Am Soc Nephrol 2011; 22: 1748–1757.

39.

Sola-Del Valle

D.A.

, Mohan

, Cheng

J.T.

Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy.

Nephrol Dial Transplant 2011; 26: 2387–2390.

40.

Allavena

, Bach-Ngohou

, Billaud

Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.

J Antimicrob Chemother 2013; 68: 2866–2870.

41.

Secemsky

E.A.

, Scherzer

, Nitta

Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals.

JACC Heart Fail 2015; 3: 591–599.

42.

Janssen

, Huson

M.A.

, Belard

TB and HIV in the central African region: current knowledge and knowledge gaps.

Infection 2014; 42: 281–294.